Meta-analyses with industry involvement are massively published and report no caveats for antidepressants

Journal of Clinical Epidemiology

Volumn 70, Issue , 2016, Pages 155-163

  Ebrahim, Shanil ^a,b,c   Bance, Sheena ^d   Athale, Abha ^d   Malachowski, Cindy ^a   Ioannidis, John P A ^a,e  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MCMASTER UNIVERSITY   (Canada)

^c HOSPITAL FOR SICK CHILDREN   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e STANFORD UNIVERSITY   (United States)

Author keywords

Antidepressants; Competing interests; Conflicts of interest; Depression; Industry sponsor; Meta analyses

Indexed keywords

ANTIDEPRESSANT AGENT; ATYPICAL ANTIDEPRESSANT AGENT; MONOAMINE OXIDASE INHIBITOR; NEUROLEPTIC AGENT; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TETRACYCLIC ANTIDEPRESSANT AGENT; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG;

ARTICLE; CONFLICT OF INTEREST; DEPRESSION; DRUG EFFICACY; DRUG MANUFACTURE; DRUG SAFETY; EMPLOYEE; HUMAN; INDUSTRY; META ANALYSIS (TOPIC); PRIORITY JOURNAL; PUBLICATION; DRUG INDUSTRY; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANTIDEPRESSIVE AGENTS; CONFLICT OF INTEREST; DEPRESSION; DRUG INDUSTRY; HUMANS; META-ANALYSIS AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84957436286     PISSN: 08954356     EISSN: 18785921     Source Type: Journal    
DOI: 10.1016/j.jclinepi.2015.08.021     Document Type: Article

References (32)

1. D. Moher, J. Tetzlaff, A.C. Tricco, M. Sampson, and D.G. Altman Epidemiology and reporting characteristics of systematic reviews PLos Med 4 2007 e78
2. E. Stamatakis, R. Weiler, and J.P. Ioannidis Undue industry influences that distort healthcare research, strategy, expenditure and practice: a review Eur J Clin Invest 43 2013 469 475
3. A.W. Jørgensen, K.L. Maric, B. Tendal, A. Faurschou, and P.C. Gøtzsche Industry-supported meta-analyses compared with meta-analyses with non-profit or no support: differences in methodological quality and conclusions BMC Med Res Methodol 9 2008 60
4. A.W. Jørgensen, J. Hilden, and P.C. Gøtzsche Cochrane reviews compared with industry supported meta-analyses and other meta-analyses of the same drugs: systematic review BMJ 333 2006 782
5. B. Djulbegovic, A. Kumar, B. Miladinovic, T. Reljic, S. Galeb, A. Mhaskar, and et al. Treatment success in cancer: industry compared to publicly sponsored randomized controlled trials PLoS One 8 2013 e58711
6. A. Lundh, S. Sismondo, J. Lexchin, O.A. Busuioc, and L. Bero Industry sponsorship and research outcome Cochrane Database Syst Rev 12 2012 MR000033
7. R.J. Kelly, L.J. Cohen, R.J. Semple, P. Bialer, A. Lau, A. Bodenheimer, and et al. Relationship between drug company funding and outcomes of clinical psychiatric research Psychol Med 36 2006 1647 1656
8. U.S. Anti-Depressant Market - Old Fashion Branding Could Save The Day. Available at http://www.researchandmarkets.com/research/p35qmw/u-s. Accessed February 26, 2014.
9. T.A. Hammad, T. Laughren, and J. Racoosin Suicidality in pediatric patients treated with antidepressant drugs Arch Gen Psychiatry 63 2006 332 339
10. Relationship between psychotropic drugs and pediatric suicidality: review and evaluation of clinical data. Available at http://www.fda.gov/ohrms/dockets/ac/04/briefing/2004-4065b1-10-TAB08-Hammads-Review.pdf ]. Accessed February 26, 2014.
11. I. Kirsch, B.J. Deacon, T.B. Huedo-Medina, A. Scoboria, T.J. Moore, and B.T. Johnson Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration PLos Med 5 2008 e45
12. A.B. Haidich, D. Pilalas, D.G. Contopoulos-Ioannidis, and J.P. Ioannidis Most meta-analyses of drug interventions have narrow scopes and many focus on specific agents J Clin Epidemiol 66 2013 371 378
13. S. Chimonas, Z. Frosch, and D.J. Rothman From disclosure to transparency: the use of company payment data Arch Intern Med 171 2011 81 86
14. D.R. Guay Vilazodone hydrochloride, a combined SSRI and 5-HT1A receptor agonist for major depressive disorder Consult Pharm 27 2012 857 867
15. R. Fleurence, R. Williamson, Y. Jing, E. Kim, Q.V. Tran, A.S. Pikalov, and et al. A systematic review of augmentation strategies for patients with major depressive disorder Psychopharmacol Bull 42 3 2009 57 90
16. D.S. Robinson, M.L. Gilmor, Y. Yang, G. Moonsammy, A.J. Azzaro, D.A. Oren, and et al. Treatment effects of selegiline transdermal system on symptoms of major depressive disorder: a meta-analysis of short-term, placebo-controlled, efficacy trials Psychopharmacol Bull 40 3 2007 15 28
17. T. Reynolds Industry-funded versus publicly funded trials: are the standards the same? J Natl Cancer Inst 93 2001 1590 1592
18. O. Thomas, L. Thabane, J. Douketis, R. Chu, A.O. Westfall, and D.B. Allison Industry funding and the reporting quality of large long-term weight loss trials Int J Obes (Lond) 32 2008 1531 1536
19. N.A. Khan, J.I. Lombeida, M. Singh, H.J. Spencer, and K.D. Torralba Association of industry funding with the outcome and quality of randomized controlled trials of drug therapy for rheumatoid arthritis Arthritis Rheum 64 2012 2059 2067
20. P. Peura, J.A. Martikainen, T.T. Purmonen, and J.H. Turunen Sponsorship-related outcome selection bias in published economic studies of triptans: systematic review Med Decis Making 32 2012 237 245
21. D. Lathyris, N.A. Patsopoulos, G. Salanti, and J.P. Ioannidis Industry sponsorship and selection of comparators in randomized clinical trials Eur J Clin Invest 40 2010 172 182
22. V. Yank, D. Rennie, and L.A. Bero Financial ties and concordance between results and conclusions in meta-analyses: retrospective cohort study BMJ 335 2007 1202 1205
23. A.G. Dunn, D. Arachi, J. Hudgins, G. Tsafnat, E. Coiera, and F.T. Bourgeois Financial conflicts of interest and conclusions about neuraminidase inhibitors for influenza: an analysis of systematic reviews Ann Intern Med 161 2014 513 518
24. A. Fugh-Berman, C.P. McDonald, A.M. Bell, E.C. Bethards, and A.R. Scialli Promotional tone in reviews of menopausal hormone therapy after the Women's Health Initiative: an analysis of published articles PLos Med 8 2011 e1000425
25. C.S. Hartog, H. Skupin, C. Natanson, J. Sun, and K. Reinhart Systematic analysis of hydroxyethyl starch (HES) reviews: proliferation of low-quality reviews overwhelms the results of well-performed meta-analyses Intensive Care Med 38 2012 1258 1271
26. A. Tatsioni, G.C. Siontis, and J.P. Ioannidis Partisan perspectives in the medical literature: a study of high frequency editorialists favoring hormone replacement therapy J Gen Intern Med 25 2010 914 919
27. S. Brunton, F. Wang, S.B. Edwards, A.S. Crucitti, M.J. Ossanna, D.J. Walker, and et al. Profile of adverse events with duloxetine treatment: a pooled analysis of placebo-controlled studies Drug Saf 33 2010 393 407
28. Report development. Available at http://www.ahrq.gov/clinic/epc/. Accessed June 2, 2014.
29. Finding what works in health care: standards for systematic reviews. Available at http://www.nap.edu/catalog.php?record-id=13059
30. P.C. Gøtzsche, and J.P. Ioannidis Content area experts as authors: helpful or harmful for systematic reviews and meta-analyses? BMJ 345 2012 e7031
31. R. Smith, P.C. Gøtzsche, and T. Groves Should journals stop publishing research funded by the drug industry? BMJ 348 2014 g171
32. K.C. Siontis, T. Hernandez-Boussard, and J.P. Ioannidis Overlapping meta-analyses on the same topic: survey of published studies BMJ 347 2013 f4501